These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 24453963)

  • 1. From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer.
    Ilkow CS; Swift SL; Bell JC; Diallo JS
    PLoS Pathog; 2014 Jan; 10(1):e1003836. PubMed ID: 24453963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic viruses & their specific targeting to tumour cells.
    Singh PK; Doley J; Kumar GR; Sahoo AP; Tiwari AK
    Indian J Med Res; 2012 Oct; 136(4):571-84. PubMed ID: 23168697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses.
    De Silva N; Atkins H; Kirn DH; Bell JC; Breitbach CJ
    Cytokine Growth Factor Rev; 2010; 21(2-3):135-41. PubMed ID: 20338801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virotherapy: From single agents to combinatorial treatments.
    Malfitano AM; Di Somma S; Iannuzzi CA; Pentimalli F; Portella G
    Biochem Pharmacol; 2020 Jul; 177():113986. PubMed ID: 32330494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Genetic, immunological, and pharmacological strategies to generate improved oncolytic viruses].
    Pol J; Le Bœuf F; Diallo JS
    Med Sci (Paris); 2013 Feb; 29(2):165-73. PubMed ID: 23452603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent advances in oncolytic virus-based cancer therapy.
    Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
    Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Going viral with cancer immunotherapy.
    Lichty BD; Breitbach CJ; Stojdl DF; Bell JC
    Nat Rev Cancer; 2014 Aug; 14(8):559-67. PubMed ID: 24990523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SnapShot: Cancer Immunotherapy with Oncolytic Viruses.
    Gujar S; Bell J; Diallo JS
    Cell; 2019 Feb; 176(5):1240-1240.e1. PubMed ID: 30794777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining oncolytic virotherapy and tumour vaccination.
    Bridle BW; Hanson S; Lichty BD
    Cytokine Growth Factor Rev; 2010; 21(2-3):143-8. PubMed ID: 20226716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic virotherapy for urological cancers.
    Delwar Z; Zhang K; Rennie PS; Jia W
    Nat Rev Urol; 2016 Jun; 13(6):334-52. PubMed ID: 27215429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bugs and drugs: oncolytic virotherapy in combination with chemotherapy.
    Wennier ST; Liu J; McFadden G
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1817-33. PubMed ID: 21740354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant viruses with other anti-cancer therapeutics: a step towards advancement of oncolytic virotherapy.
    Lal G; Rajala MS
    Cancer Gene Ther; 2018 Oct; 25(9-10):216-226. PubMed ID: 29735993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.
    Breitbach CJ; Reid T; Burke J; Bell JC; Kirn DH
    Cytokine Growth Factor Rev; 2010; 21(2-3):85-9. PubMed ID: 20472490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer.
    Nettelbeck DM
    J Mol Med (Berl); 2008 Apr; 86(4):363-77. PubMed ID: 18214411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Viruses as nanomedicine for cancer.
    Badrinath N; Heo J; Yoo SY
    Int J Nanomedicine; 2016; 11():4835-4847. PubMed ID: 27703350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.
    Cuddington BP; Mossman KL
    J Virol; 2014 Jun; 88(12):6885-95. PubMed ID: 24696490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.
    Breitbach CJ; Thorne SH; Bell JC; Kirn DH
    Curr Pharm Biotechnol; 2012 Jul; 13(9):1768-72. PubMed ID: 21740365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex vivo infection of live tissue with oncolytic viruses.
    Diallo JS; Roy D; Abdelbary H; De Silva N; Bell JC
    J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour vasculature: Friend or foe of oncolytic viruses?
    Santry LA; van Vloten JP; Knapp JP; Matuszewska K; McAusland TM; Minott JA; Mould RC; Stegelmeier AA; Major PP; Wootton SK; Petrik JJ; Bridle BW
    Cytokine Growth Factor Rev; 2020 Dec; 56():69-82. PubMed ID: 32893095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.